Clinical trials
Pancreatitis clinical trials
Below are recruiting pancreatitis clinical trials, each written for real people, not researchers. We’re tracking 1,040 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06508307RecruitingPhase 1
A study of an injected virus for advanced solid tumors
This trial tests a new treatment where a virus (GC001) is injected directly into a tumor. The virus is designed to attack cancer cells and may help people with advanced solid tumors that haven't responded to other treatments.
Zhengzhou, HenanAges 18–75 - NCT06533332RecruitingPhase 1
Testing ERX-315 for advanced solid tumors
This trial tests a new drug called ERX-315 for people with advanced solid tumors (like breast, ovarian, pancreatic, endometrial, or liver cancer) that have not responded to standard treatments. The goal is to see if the drug is safe and how well it works.
Ryde, New South WalesAges 18 years+ - NCT06539806Recruiting
Losartan for pancreatic cancer with high blood pressure
This trial tests if adding losartan (a blood pressure medicine) to standard chemotherapy helps people with advanced pancreatic cancer. It is for patients who also have high blood pressure.
TantaAges 50–85 - NCT06572813RecruitingPhase 1/Phase 2
Combination therapy for advanced pancreatic cancer
This trial tests whether adding bortezomib and an immunotherapy drug to standard chemotherapy can help people with pancreatic cancer that has spread to other organs. It is for patients who have not had treatment or whose cancer has worsened after gemcitabine-based chemotherapy.
Hangzhou, ZhejiangAges 18–75 - NCT06575426RecruitingPhase 1/Phase 2
Testing pig pancreas cells for type 1 diabetes
This trial tests a treatment made from pig pancreas cells (OPF-310) to see if it's safe and can help people with unstable type 1 diabetes. The cells are meant to replace the insulin-producing cells your body has lost, potentially reducing dangerous low blood sugar events.
Chicago, IllinoisAges 35–65 - NCT06577532RecruitingEarly Phase 1
KRAS mRNA vaccine for advanced solid tumors
This early-phase trial is testing a new mRNA vaccine (ABO2102) designed to target KRAS mutations in advanced solid tumors. It may be an option if your cancer has a KRAS mutation and standard treatments are no longer working.
ShanghaiAges 18 years+ - NCT06578052Recruiting
Irinotecan liposome with capecitabine for advanced pancreatic cancer
This trial tests a combination of two chemotherapy drugs (irinotecan liposome and capecitabine) for people with pancreatic cancer that has spread or cannot be removed by surgery and has gotten worse after initial treatment. The goal is to see if this combination can help slow the disease.
Shenzhen, GuangdongAges 18–80 - NCT06586515RecruitingPhase 1
Testing a new drug for cancers with KRAS G12D mutation
This trial tests a new pill (LY3962673) for people whose cancer has a specific DNA change called KRAS G12D. The drug aims to block the faulty protein that helps the cancer grow, and the study will look at safety and whether the tumor shrinks.
Duarte, CaliforniaAges 18 years+ - NCT06592989Recruiting
Sorafenib and gefitinib for advanced pNET
This trial tests a combination of two targeted drugs (sorafenib and gefitinib) for people with pancreatic neuroendocrine tumors (pNETs) that have continued to grow after other treatments. The goal is to see if this combination can help control the tumor.
Shanghai, Shanghai MunicipalityAges 18–80 - NCT06596915RecruitingPhase 1
BA1302 for advanced solid tumors
This trial tests a new drug, BA1302, for people with advanced solid tumors that have stopped responding to standard treatments. The study aims to see if BA1302 is safe and effective.
BeijingAges 18 years+ - NCT06598007RecruitingPhase 1/Phase 2
Studying CT3001 for advanced solid tumors
This study tests an experimental drug called CT3001 for people with advanced solid tumors that haven't responded to other treatments. The goal is to see if it's safe and effective, and for some patients with colorectal cancer, it may be combined with standard chemotherapy.
Houston, TexasAges 18 years+ - NCT07529808RecruitingPhase 1/Phase 2
New Drug BHB810 for Advanced Stomach Cancer
This trial tests a new drug called BHB810 for gastric (stomach) and gastroesophageal junction cancer that has stopped responding to standard treatments or has no standard options available. The drug targets a protein called CDH17 found on cancer cells and may help slow or shrink the tumor.
Fairfax, VirginiaAges 18 years+ - NCT06605404Recruiting
Pan-tumor study of a blood test after cancer surgery
This study is testing a new blood test that looks for leftover cancer cells after surgery. It is for people with different types of solid tumors who are planning to have surgery to cure their cancer. The goal is to see if the test can help guide future treatment decisions.
San Diego, CaliforniaAges 18 years+ - NCT06617169RecruitingPhase 1
Radioactive drug for solid tumors after prior study
This trial tests a new radioactive drug called MNPR-101-PCTA-177Lu for people with solid tumors who already completed a previous study (MNPR-101-D001). It aims to find the safest and most effective dose by carefully monitoring how your body handles the treatment.
North Melbourne, VictoriaAges 18 years+ - NCT06632886Recruiting
AI study to find cancers from your past CT scans
This study uses artificial intelligence to look at CT scans you've already had (without dye) to try and find signs of several types of cancer early. It may help find cancer sooner when it's easier to treat.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06673329RecruitingPhase 1
Brodalumab for immune-related side effects from cancer treatment
This trial tests if brodalumab, an antibody that blocks a specific immune pathway (IL-17), can help control side effects caused by immunotherapy cancer treatment. It is for people with advanced solid organ cancers who have immune-related side effects that are suspected to involve IL-17.
New York, New YorkAges 18 years+ - NCT06694792Recruiting
Study on markers to find invasive IPMN
This trial looks for markers in cyst fluid and tissue to help identify which IPMN growths are becoming invasive (spreading). It may help doctors decide who needs surgery.
Milan, MIAges 18 years+ - NCT06695845RecruitingPhase 2
Study of zanidatamab for HER2-positive solid tumors
This trial tests a drug called zanidatamab in people with advanced solid tumors that have high levels of HER2 protein (called HER2-positive). It aims to see if zanidatamab can shrink or slow the growth of these tumors.
Prescott, ArizonaAges 18 years+ - NCT06698302Recruiting
Validation of a Spanish pain questionnaire (COMPAT-SF)
This study asks Spanish-speaking people with chronic pancreatitis to fill out a questionnaire about their pain. It aims to test whether a Spanish version of the COMPAT (a pain-assessment tool) works well.
Dallas, TexasAges 18 years+ - NCT06706700Recruiting
Biomarkers to predict cancer risk in pancreatic IPMN
This trial studies whether blood markers can help predict which pancreatic IPMNs are likely to become cancerous. If successful, it could help doctors decide when surgery is needed.
Milan, ItalyAges 18 years+ - NCT07300150RecruitingPhase 1
PT0511 for KRAS-mutated or amplified advanced solid tumors
This trial tests a new drug called PT0511 that targets a specific gene change (KRAS) found in some advanced solid tumors. It's for people whose cancer has not responded well to other treatments and who are looking for a new option.
Boston, MassachusettsAges 18 years+ - NCT04389632RecruitingPhase 1
Sigvotatug vedotin for advanced solid tumors that spread
This early-stage study tests a drug called sigvotatug vedotin in people with advanced solid cancers that cannot be removed or have spread. It aims to see how well the treatment works and what side effects it causes.
Anchorage, AlaskaAges 18 years+ - NCT06737341RecruitingPhase 4
Liposomal vs. Standard Bupivacaine for Pain after Keyhole Abdominal Surgery
This trial tests whether a long-acting numbing medicine (liposomal bupivacaine) works better than standard bupivacaine to control pain after keyhole surgery on the liver, bile ducts, or pancreas. It may help you experience less pain and need fewer painkillers after surgery.
Wuhan, HubeiAges 18–80 - NCT07224750Recruiting
A blood test to find early signs of gastrointestinal cancer
This study is testing a blood-based test to detect unique molecules (called miRNAs) that may signal the presence of several types of gut or digestive system cancers. The goal is to develop a simple screening tool that could catch these cancers earlier.
Duarte, CaliforniaAges 18 years+
Hear when a new Pancreatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for pancreatitis?
- Yes. Clin2 currently lists 1,040 recruiting pancreatitis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a pancreatitis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a pancreatitis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.